Compare AbCellera Biologics Inc (ABCL) vs Ralph Lauren Corp (RL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Ralph Lauren Corp — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Ralph Lauren Corp trades at $385.59 (market cap $23.53B). The key difference: Ralph Lauren Corp is far larger — about 10× AbCellera Biologics Inc's market cap, and Ralph Lauren Corp pays a 0.95% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | RL | |
|---|---|---|
Market Cap | $2.35B | $23.53B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $414.25 |
52-Week Low | $2.78 | $283.34 |
Enterprise Value | $1.99B | $24.47B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Ralph Lauren (RL) trades at $395.31, down 0.73% on the day, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.80 surpassing expectations. Revenue growth accelerated to $7.08 billion in 2025, while net income margin improved to 10.49%. Analyst consensus remains strongly bullish with a $446.25 price target, representing 13% upside potential from current levels.
RL presents a compelling growth story with expanding margins and strategic initiatives driving performance. Key risks include consumer discretionary spending sensitivity and competitive pressures in the apparel sector. The company's digital expansion and Next Great Chapter strategy provide catalysts for continued outperformance, though macroeconomic headwinds could impact near-term results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
